JP5948687B1 - A biofilm for the purpose of promoting wound healing and covering (coaching) and protecting living organs. - Google Patents

A biofilm for the purpose of promoting wound healing and covering (coaching) and protecting living organs. Download PDF

Info

Publication number
JP5948687B1
JP5948687B1 JP2015169762A JP2015169762A JP5948687B1 JP 5948687 B1 JP5948687 B1 JP 5948687B1 JP 2015169762 A JP2015169762 A JP 2015169762A JP 2015169762 A JP2015169762 A JP 2015169762A JP 5948687 B1 JP5948687 B1 JP 5948687B1
Authority
JP
Japan
Prior art keywords
water
tannin
biofilm
aluminum chloride
wound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015169762A
Other languages
Japanese (ja)
Other versions
JP2017035425A (en
Inventor
亮一 平岩
亮一 平岩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lilac Laboratory Co., Ltd.
Original Assignee
Lilac Laboratory Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilac Laboratory Co., Ltd. filed Critical Lilac Laboratory Co., Ltd.
Priority to JP2015169762A priority Critical patent/JP5948687B1/en
Application granted granted Critical
Publication of JP5948687B1 publication Critical patent/JP5948687B1/en
Publication of JP2017035425A publication Critical patent/JP2017035425A/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

【課題】創傷面、及び障害性細胞に対し、極めて薄い撥水及び脱脂両特性を有する被膜を形成し、創傷面及び障害性細胞を被覆し、障害性細胞からの細胞内液の漏出を防ぎ、炎症反応を防ぐことにより、自発性疼痛を緩和し、創傷治癒を促進する創傷被覆剤、及び諸臓器内外面の細胞密着型被覆剤、及び庇護剤として、縫合部位、血管吻合、開腹手術による炎症反応に伴う腸管浮腫を抑制し、癒着性イレウス等を防止することを目的とする生体皮膜剤の提供。【解決手段】主剤として塩化アルミニウムとシクロデキストリンとタンニン(タンニン酸)と水とを含む生体皮膜剤。水100部に対し、塩化アルミニウムが0.01〜25.0重量%、シクロデキストリンが0.1〜45重量%及びタンニン(タンニン酸)が0.01〜50.0重量%である、生体皮膜剤。主剤となる水が、体液中の水分(汗汁、涙液、唾液、血液、胃液等々の生体水分)である生体皮膜剤。【選択図】なしAn object of the present invention is to form a coating film having both extremely thin water-repellent and degreasing properties on a wound surface and a damaged cell to cover the wound surface and the damaged cell and prevent leakage of intracellular fluid from the damaged cell. As a wound dressing that prevents spontaneous inflammation by preventing inflammatory reaction and promotes wound healing, and cell adhesion type coating on internal and external surfaces of various organs, and as a protective agent, by suture site, vascular anastomosis, laparotomy Provided is a biofilm for the purpose of suppressing intestinal edema associated with an inflammatory reaction and preventing adhesive ileus and the like. A biofilm agent comprising aluminum chloride, cyclodextrin, tannin (tannic acid) and water as main ingredients. Biological membrane comprising aluminum chloride in an amount of 0.01 to 25.0% by weight, cyclodextrin in an amount of 0.1 to 45% by weight and tannin (tannic acid) in an amount of 0.01 to 50.0% by weight with respect to 100 parts of water. Agent. A biofilm agent in which water as a main ingredient is water in body fluids (biological water such as sweat, tears, saliva, blood, gastric juice, etc.). [Selection figure] None

Description

発明の属する分野Field of Invention

本発明は、出願番号2014−246275の改良発明であり、創傷面、及び障害性細胞に対し、極めて薄い撥水及び脱脂両特性を有する被膜を形成し、創傷面及び障害性細胞を被覆し、障害性細胞からの細胞内液の漏出を防ぎ、炎症反応を防ぐことにより、自発性疼痛を緩和し、創傷治癒を促進する創傷被覆剤、及び諸臓器内外面の細胞密着型被覆剤、及び庇護剤として、縫合部位、血管吻合、開腹手術による炎症反応に伴う腸管浮腫を抑制し、癒着性イレウス等を防止することを目的とする生体皮膜剤の改良発明に関する。創傷面、及び諸臓器及び、諸臓器障害部位、並びに筋肉・筋膜等の軟部組織、骨膜、骨皮質に達する創傷面での被覆及び庇護を目的とし、塩化アルミニウム・シクロデキストリン・水を含み、加えて植物由来のポリフェノール化合物からなる、取り分け慣用名タンニン(タンニン酸)よりなる本願発明の生体被覆剤を塗布、乃至は散布することで、細胞密着型被膜の安静及び安定性が確保されて、より高い創傷治癒の実現が可能とる。The present invention is an improved invention of application number 2014-246275, and forms a coating having extremely thin water-repellent and degreasing properties on the wound surface and the damaged cells, and coats the wound surface and the damaged cells, Wound dressing that relieves spontaneous pain and promotes wound healing by preventing leakage of intracellular fluid from impaired cells and preventing inflammatory response, and cell adhesion type coating for internal and external surfaces of various organs, and protection The present invention relates to an improved invention of a biofilm agent for the purpose of suppressing intestinal edema associated with an inflammatory reaction caused by a suture site, vascular anastomosis, laparotomy, and preventing adhesive ileus. For the purpose of covering and protecting the wound surface and various organs, various organ damage sites, and soft tissues such as muscle and fascia, periosteum and bone cortex, including aluminum chloride, cyclodextrin, water, In addition, by applying or spraying the biocoating agent of the present invention consisting of a plant-derived polyphenol compound, especially the commonly used name tannin (tannic acid), the rest and stability of the cell-adhesive coating are ensured, Realization of higher wound healing is possible.

これまで、主剤として塩化アルミニウムとシクロデキストリンと水とを含み、該主剤とする創傷用被膜剤、出願番号2014−246275を開発したが、該創傷被膜剤の皮膜の厚みは極めて薄く、毛髪の刺激、衣類による摩擦、日常生活動作中に、いつの間にか生じる二次的外力から安静が保ちにくい難点がある。患部が擦れて出血した場合には、その都度、患部の疼痛が出現し、痂皮(かさぶた)が形成される等、創傷部への予測し難い新たな外傷がもたらすダメージは、創傷治癒の遅延、及び色素沈着の増加、瘢痕(傷跡)の赤み、凹凸等の醜形が見られる等、皮膜剤の物理的強度改善が求められていた。Up to now, the wound coating agent, which has aluminum chloride, cyclodextrin and water as the main ingredients and has been developed as the main ingredient, application number 2014-246275 has been developed. There is a difficulty that it is difficult to keep rest from secondary external force that occurs in the course of friction caused by clothing and daily life. Each time the affected area rubs and bleeds, the pain of the affected area appears and the formation of scabs (scabs) causes damage to the wound that is difficult to predict. Further, there has been a demand for improvement in the physical strength of the coating agent, such as increased pigmentation, redness of scars (scars), and wrinkles such as irregularities.

周囲皮膚との質感の改善を妨げる諸要因を取り除くことで、創傷治癒力が適正化され、より簡便に、創の深さにより生じる治癒期間の遷延に関わらず目立たない状態に皮膚を修復させることが可能となる。By removing the factors that hinder the improvement of the texture with the surrounding skin, the wound healing power is optimized, and more easily, the skin is repaired in an inconspicuous state regardless of the prolonged healing period caused by the wound depth Is possible.

前願発明の創傷皮膜剤の皮膜をより強靭に、且つ安定した皮膜持続性を保持するためには、皮膚刺激性を緩和する働きのある植物由来のポリフェノール化合物、取り分けタンニン(タンニン酸)の皮膜性に注目しものである。さらに塩化アルミニウムとシクロデキストリンと水により形成される皮膜組成物と親和性があり、前願発明がもつ諸々の作用効果を阻害せず、しかもシナジー効果の高い複合皮膜に着眼し本発明を完成させた。In order to maintain the toughness and stable film durability of the film of the wound film preparation of the invention of the previous application, a plant-derived polyphenol compound that acts to alleviate skin irritation, especially tannin (tannic acid) film Pay attention to sex. Furthermore, the present invention has been completed by focusing on a composite film that has an affinity with a film composition formed of aluminum chloride, cyclodextrin and water, does not inhibit the various effects of the invention of the prior application, and has a high synergistic effect. It was.

発明が解決しようとする課題Problems to be solved by the invention

植物由来のポリフェノール化合物であり、慣用名タンニン(タンニン酸)は塩化アルミニウムと同種の皮膜撥水作用、及び収斂作用を持ち、分子量が大きいので、塩化アルミニウムのもつ皮膜効果の数百倍は有ると考えられる厚い撥水性被膜を形成する働きがある。更にその皮膜は水蒸気等のガス透過性をもつポーラス状薄膜を形成する特徴があり、且つタンパク質と結合して凝固作用を有することから、皮膚・皮下・筋膜・筋肉・骨膜・骨皮質表面に及ぶ外傷に対し、塩化アルミニウム・シクロデキストリン・タンニン(タンニン酸)・水とを含む相互作用により、創傷部位に塗布乃至は散布することで、フィブリンの産生抑制により抗凝固特性を有し、障害細胞、破損細胞の断面に対し3次元的ミクロの撥水脱脂性消炎性被膜が形成され、加えて皮膜創傷面から僅かに滲出する血漿タンパク質と血液を凝固させる作用があることから、塩化アルミニウム・シクロでキストリン・タンニン(タンニン酸)を骨格とする痂皮類似性の強固な被膜が形成される。It is a plant-derived polyphenol compound, and the common name tannin (tannic acid) has the same kind of film water-repellent and astringent action as aluminum chloride and has a large molecular weight, so it has several hundred times the film effect of aluminum chloride. It has the function of forming a possible thick water-repellent coating. Furthermore, the film has a characteristic of forming a porous thin film with gas permeability such as water vapor, and has a coagulation action by binding to protein, so it is applied to the surface of skin, subcutaneous, fascia, muscle, periosteum, and bone cortex. By applying or spraying to the wound site by the interaction including aluminum chloride, cyclodextrin, tannin (tannic acid), and water, it has anticoagulant properties by suppressing fibrin production and damaged cells In addition, a three-dimensional microscopic water-repellent degreasing anti-inflammatory coating is formed on the cross section of the damaged cell, and in addition, there is an action of coagulating blood plasma protein and blood slightly exuding from the wound surface of the membrane. As a result, a strong crust-like film having a skeleton of xistrin tannin (tannic acid) is formed.

この皮膜形成により抗凝固消炎機能が増し、これまでの生体被膜剤の安定性が大幅に改善強化される。創傷面に塗布後30分〜2時間で、淡い肌色調の一痂皮類似性被膜が形成される。即ち塩化アルミニウム・シクロデキストリン・水との相互作用では得られなかった、タンニン(タンニン酸)よる強固な複合被膜が形成される。加えて塩化アルミニウムによる患部、創傷部への刺激感をpHに依存することなく和らげる、タンニン(タンニン酸)の緩衝剤的働きにも注目した。By forming this film, the anticoagulant / anti-inflammatory function is increased, and the stability of conventional biofilms is greatly improved and enhanced. A single skin-like film with a light skin tone is formed 30 minutes to 2 hours after application to the wound surface. That is, a strong composite film made of tannin (tannic acid) that cannot be obtained by the interaction with aluminum chloride, cyclodextrin, and water is formed. In addition, we focused on the buffering action of tannin (tannic acid), which relieves the feeling of irritation to the affected and wounded areas by aluminum chloride without depending on pH.

該皮膜剤の塗布後、24時間経過後、複合被膜は創傷面の赤血球と融合し血痂(血のかさぶた)を形成させ、疼痛が顕著に低減され、患部はガーゼを当てることなく、開放とした状態でもドライな創傷管理が可能となった。本剤の継続塗布により形成された血痂の表面にも、塩化アルミニウム・シクロデキストリン・タンニン(タンニン酸)よる複合被膜が形成される為、毎日、1〜2回の塗布だけで安定した被膜の維持継続が可能となり、しかも創傷部位の二次的外傷の機会も減少するので患部の安静が保持され、創傷部位の表皮化治癒後、或いは瘢痕治癒後の外傷後色素沈着を大きく低減できる。24 hours after application of the film, the composite film fuses with red blood cells on the wound surface to form a blood clot (blood scab), pain is remarkably reduced, and the affected area is opened without gauze. Dry wound management became possible even under the condition. Since a composite coating of aluminum chloride, cyclodextrin, and tannin (tannic acid) is also formed on the surface of the clot formed by continuous application of this agent, a stable coating can be obtained only once or twice daily. Maintenance can be continued, and the chance of secondary trauma at the wound site is also reduced, so that the rest of the affected area is maintained, and post-traumatic pigmentation after healing of the wound site or after scar healing can be greatly reduced.

また、塩化アルミニウム・シクロデキストリン・タンニン(タンニン酸)よる複合被膜は、痂皮と創部辺縁の表皮との境界部位にも同様に複合被膜を形成する為、創傷面の新生した表皮と痂皮の境界部位に軽微な摩擦力や引張力、剪断力が加わった場合でも、新生した表皮を傷つけることなく、血痂の剥離を早める効果が得られる。血痂が剥がれた後の創傷面と周囲皮膚との段差は創傷の深度に依存するが、表皮化後1ヵ月から1〜2年の間に瘢痕部に生じる軽度の隆起は肉眼では認めらない。In addition, the composite film made of aluminum chloride, cyclodextrin, and tannin (tannic acid) also forms a composite film at the boundary between the scab and the epidermis of the wound edge, so that the new epidermis and scab of the wound surface are formed. Even if a slight frictional force, tensile force, or shearing force is applied to the boundary portion of the skin, the effect of accelerating clot detachment can be obtained without damaging the new epidermis. The level difference between the wound surface and the surrounding skin after the clot has peeled depends on the depth of the wound, but the mild bumps that appear in the scar between 1 month and 1 to 2 years after the epidermis are not visible to the naked eye. .

これは、塩化アルミニウムとシクロデキストリンとタンニン(タンニン酸)により形成される複合被膜が、線維芽細胞の過剰増殖や膠原線維の過剰産生を抑え最適化する働きによるもので、軽微に隆起してくる肉芽組織の膨隆を該複合皮膜によって早期の痂皮類似性被膜と早期血痂形成による強固な板状構造を形成することから圧迫整形がなされ、肉芽組織表面との両被膜間をガードしているので創縁から表皮細胞が平坦に新生伸長することを可能ならしめたと考えられる。また、塩化アルミニウムとシクロデキストリンと水とにより、過剰の炎症反応の回避、抑制作用とタンニン(タンニン酸)による早期の血痂形成作用とによる紫外線抑止効果は、炎症後色素沈着や紫外線による色素増強を低減し外傷性(炎症性)色素沈着を抑止することから、創傷治癒後、周囲皮膚との色調差も少なく、外傷後の皮膚の醜状も顕著に回避できる。This is because the composite coating formed by aluminum chloride, cyclodextrin, and tannin (tannic acid) works by suppressing and optimizing fibroblast overgrowth and collagen fiber overproduction, and is slightly raised The bulge of granulation tissue is formed by compression molding because it forms an early crust-like coating and a strong plate-like structure by early clot formation by the composite coating, and guards between both coatings with the granulation tissue surface Therefore, it is thought that it was possible to make the epidermal cells flat and new from the wound edge. In addition, aluminum chloride, cyclodextrin, and water prevent excessive inflammatory reaction, suppress UV rays, and prevent UV rays by tannin (tannic acid) early clot formation. Is reduced, and traumatic (inflammatory) pigmentation is suppressed, so that after wound healing, there is little difference in color with the surrounding skin, and wrinkles on the skin after trauma can be avoided significantly.

課題を解決する為の手段Means to solve the problem

生体皮膜剤を構成するには水は必須の構成要素であり、生体皮膜剤は以下の条件で構成される。精製水100gに対して、重量比で塩化アルミニウムを0.1〜25%、シクロデキストリンを0.1〜45%、皮膜の厚みを考慮すれば、タンニン濃度は0.01〜50%の範囲内で使用するのが好ましい。ヒドロキシアルミニウム塩として、塩化アルミニウムは無水でも、水和物でも使用できるが、効果は劣るが、クロルヒドロキシアルミニウム、明礬、塩基性塩化アルミニウム等の重合体でも利用できる。Water is an essential component for constituting the biofilm agent, and the biofilm agent is constituted under the following conditions. The tannin concentration is within the range of 0.01 to 50% with respect to 100 g of purified water, considering aluminum chloride in the weight ratio of 0.1 to 25%, cyclodextrin in the range of 0.1 to 45%, and film thickness. Is preferably used. As the hydroxyaluminum salt, aluminum chloride can be used in anhydrous form or hydrate, but the effect is inferior, but it can also be used in polymers such as chlorohydroxyaluminum, alum and basic aluminum chloride.

血液の漏出や浸出液等の過剰な水分(体液)を含む創傷部位で使用するには、粉末状の剤形が好ましく、余分な浸出液を吸着しながら微粉末を含む疑似痂皮を形成しつつ、創傷部との複雑な境界面において、より有効な皮膜形成がなされる利点がある。微粉末としては本願発明の主剤となる塩化アルミニウム、シクロデキストリン、タンニン(タンニン酸)の粉末剤を、粉末ベース助剤に配合させて造る。粉末ベース助剤として無水珪酸、キカラス瓜、コーンスターチ、リン酸加工澱粉等のデンプン類、その他の粉末剤として酸化亜鉛、タルク等が挙げられる。タンニン(タンニン酸)として安価な柿渋溶液等、タンニン酸の含有溶液を予め適度に濃縮したものを、噴霧乾燥することで流動特性、混合分散性、水に対する溶解性に優れた微粉末が得られ、これらの微粉末は使用上、特に好ましいが、五倍子及び没食子等の粉砕微粉末でも十分に使用できる。For use in wound sites containing excess water (body fluid) such as blood leakage or exudate, a powdered dosage form is preferred, while forming a pseudo scab containing fine powder while adsorbing excess exudate, There is an advantage that more effective film formation is performed at a complicated interface with the wound portion. The fine powder is prepared by blending powders of aluminum chloride, cyclodextrin, and tannin (tannic acid), which are the main ingredients of the present invention, with a powder base auxiliary. Examples of the powder base auxiliary include starches such as silicic anhydride, chikarasu koji, corn starch, and phosphate processed starch, and other powders include zinc oxide and talc. By spray-drying a tannic acid-containing solution, such as inexpensive tannin (tannic acid), in advance, a fine powder with excellent fluidity, mixing and dispersibility, and water solubility can be obtained. These fine powders are particularly preferable in use, but pulverized fine powders such as pentaploid and gallic can also be used sufficiently.

本発明に用いられるシクロデキストリン(以下CDと記す)は塩化アルミニウムと水との相互作用により、皮脂や乳化物等の疎水性の物質を包接化できる包接化合物であり、本発明では主に、α−CD、β−CD、γ―CD、さらに、それらの混合組成物を指すが、それらの誘導体も利用できる。The cyclodextrin (hereinafter referred to as CD) used in the present invention is an inclusion compound that can include hydrophobic substances such as sebum and emulsion by the interaction between aluminum chloride and water. , [Alpha] -CD, [beta] -CD, [gamma] -CD, and mixtures thereof, but derivatives thereof can also be used.

ポリフェノール化合物の中でも皮膜性の高いタンニン(タンニン酸)として、縮合型タンニンと加水分解性タンニンが利用できるが、食品衛生法で「既存添加物」とする柿渋タンニン、栗皮タンニン、植物タンニンである五倍子及びタラ末又は没食子、豆科のタマリンドタンニン及びミモザタンニン、茶葉に含まれるタンニンのカテキン類とその没食子酸エステル誘導体等の加水分解性タンニン、また、紅茶のテアフラビンやテアルビジン等の縮合型タンニンの前駆体等の濃縮物も利用できるがコストパフォーマンスが低い難点がある。皮膜の厚みと強度は濃度に依存する傾向があるが、タンニン濃度として、水100gに対して重量比で1対0.5以下が使用上好ましく、下限は0.01でも皮膜を形成する特徴がある。Among the polyphenol compounds, condensed tannin and hydrolyzable tannin can be used as tannin (tannic acid) with high film property. Peptides and cod powder or gallic, hydrolyzable tannins such as catechins of tannin and its gallic acid ester derivatives contained in tea leaves, leguminous tamarind tannin and mimosa tannin, and condensed tannins such as tea theaflavin and thealvidin Concentrates such as precursors can also be used, but there is a disadvantage that cost performance is low. Although the thickness and strength of the film tend to depend on the concentration, the tannin concentration is preferably 1 to 0.5 or less in terms of a weight ratio with respect to 100 g of water. is there.

発明に使用できる剤型は用途により粉末剤、ローション、スプレー、軟膏、クリーム、チンキ剤等の剤型にも配合することができる。これらの剤型は、使用上の利点として、創傷面及び周囲皮膚に浸透するよう十分な量を塗布、適用できる点にある。The dosage form that can be used in the invention can also be blended into dosage forms such as powders, lotions, sprays, ointments, creams, tinctures and the like depending on applications. These dosage forms have the advantage that they can be applied and applied in sufficient amounts to penetrate the wound surface and surrounding skin.

必要に応じて、抗生剤、抗癌剤、免疫抑制剤、抗ヒスタミン薬、ステロイド系及び非ステロイド系消炎薬等の薬剤、プロピレングリコール、グリセリン等の保湿増粘剤、さらに粘度調整剤として通常の粘性剤が使用できるが、ヒドロキシメチルセルロース、ヒドロキシエチルセルロース、アルギン酸、ゼラチン、水溶性合成ポリマー化合物、ガム類等があるが、濃度及び混合の仕方により沈殿するので配合量や配合の順序に注意がいる。
以下に好ましい<実施例>と、その<症例>を詳述する。
Antibiotics, anticancer agents, immunosuppressive agents, antihistamines, steroidal and non-steroidal anti-inflammatory agents, moisturizing and thickening agents such as propylene glycol and glycerin, and normal viscosity agents as needed Can be used, but there are hydroxymethylcellulose, hydroxyethylcellulose, alginic acid, gelatin, water-soluble synthetic polymer compound, gums, etc., but since it precipitates depending on the concentration and mixing method, attention is paid to the blending amount and blending order.
Preferred <Example> and <Case> are described in detail below.

精製水100gに対し、塩化アルミニウム6水和物15g、β−シクロデキストリン7.5g、無水エタノール5gを混合撹拌したものにタンニン濃度5%の柿渋液を100g入れて黄色の生体皮膜剤を得た。
●本実施例による<症例1>として、44才男性、左上腕に擦過創への使用例。受傷後1時間経過後の所見(fig1)と、本皮膜剤をスプレーし、数分後に形成された複合被膜が乾いた状態(fig2)と、24時間経過後の薄い痂皮が形成された状態(fig3)を提示する。本皮膜剤を1日2回(朝・入浴後)にスプレーし乾燥させる。この動作を行い15日目には、きれいに表皮化し、色素沈着もほとんど出現しなかった(fig4)。 fig4:使用15日後を示す。
100 g of purified water was mixed with 15 g of aluminum chloride hexahydrate, 7.5 g of β-cyclodextrin, and 5 g of absolute ethanol, and 100 g of persimmon juice having a tannin concentration of 5% was added to obtain a yellow biofilm. .
As a <Case 1> according to this example, a 44-year-old male uses the left upper arm for scratching. Findings after 1 hour after injury (fig 1), sprayed with this coating agent, the composite film formed several minutes later (fig 2), and a thin scab after 24 hours (Fig3) is presented. This coating agent is sprayed twice a day (in the morning and after bathing) and dried. On the 15th day after performing this operation, the skin became clean and almost no pigmentation appeared (FIG. 4). fig4: Indicates 15 days after use.

精製水500gに対し主剤1、2を溶解、次いで3、4、5、6、7、8を加えて撹拌混合させて生体皮膜剤を得た。
1.塩化アルミニウム6水和物 45g
2.β−CD 6.5g
3.柿渋液(タンニン濃度5%) 100g
4.キサンタンガム 1.5g
5.グリセリン 20g
6.プロピレングリコール 20g
7.水酸化ナトリウムの10%溶液 150g
8.無水エタノール 10g
本実施例は、塩化アルミニウムの酸性度による患部刺激性を抑える為、水酸化ナトリウム10%溶液を添加して中和し、生じたキサンタンガムを含む沈殿物(塩化ナトリウム、水酸化アルミニウムを含む)を濾過し、pHを3.9に調整した溶液に柿渋溶液を添加して撹拌混合した。
●本実施例による<症例2>として、39歳女性。左耳介軟骨のピアスの化膿による顕著なケロイドの一例。術前の左耳介前面(fig5)、術前の左耳介後面(fig6)の画像を提示する。左耳介ケロイドを、一部耳介軟骨ごと切除し、ケロイドの皮膚を用いて全層植皮を行い、後面は縫合閉鎖した。本皮膜剤はケロイド切除後と、植皮及び縫合後にそれぞれ塗布した。抜糸後の創傷ケアは、本皮膜剤を1日2回(朝・夜)塗布し、他の薬剤は使用しなかった。術後約1ヵ月後左耳介前面(fig7)と、左耳介後面(fig8)の画像を提示する。ケロイドの再発は無く、炎症後色素沈着を認めず、周囲皮膚とのカラーマッチが良好である。fig5:術前(左耳介前面)fig6:術前(左耳介後面)
Main agents 1 and 2 were dissolved in 500 g of purified water, then 3, 4, 5, 6, 7, and 8 were added and mixed by stirring to obtain a biofilm.
1. 45 g of aluminum chloride hexahydrate
2. β-CD 6.5 g
3. 100 g of persimmon juice (tannin concentration 5%)
4). Xanthan gum 1.5g
5. Glycerin 20g
6). 20g propylene glycol
7). 150 g of 10% sodium hydroxide solution
8). Absolute ethanol 10g
In this example, in order to suppress irritation caused by the acidity of aluminum chloride, a 10% sodium hydroxide solution was added to neutralize, and the resulting precipitate containing xanthan gum (including sodium chloride and aluminum hydroxide) was added. The persimmon astringent solution was added to the solution which was filtered and the pH was adjusted to 3.9 and mixed with stirring.
● A 39-year-old female as <Case 2> according to this example. An example of a prominent keloid caused by suppuration of left ear pinna cartilage. Images of the front surface of the left auricle (fig5) and the back surface of the left auricle before the operation (fig6) are presented. A part of the left auricular keloid was excised together with the auricular cartilage, full-thickness skin grafting was performed using keloid skin, and the rear surface was closed with sutures. This coating agent was applied after keloid resection, and after skin grafting and suturing. For wound care after the removal of the thread, this film agent was applied twice a day (morning and evening), and no other drugs were used. About one month after the operation, images of the front surface of the left auricle (FIG. 7) and the rear surface of the left auricle (FIG. 8) are presented. There is no recurrence of keloid, no post-inflammation pigmentation, and good color match with surrounding skin. fig5: preoperative (front of left auricle) fig6: preoperative (rear of the left auricle)

精製水500gに対し主剤1、2を溶解、次いで4、5、6を加え、最後に3を入れて撹拌混合させて生体皮膜剤を得た。
1.塩化アルミニウム6水和物 60g
2.β−CD 5g
3.柿渋濃縮液(タンニン濃度、約10%) 50g
3.グリセリン 20g
4.プロピレングリコール 20g
5.無水エタノール 15g
The main ingredients 1 and 2 were dissolved in 500 g of purified water, then 4, 5, and 6 were added. Finally, 3 was added and stirred and mixed to obtain a biofilm.
1. Aluminum chloride hexahydrate 60g
2. β-CD 5g
3. Strawberry astringent concentrate (tannin concentration, about 10%) 50g
3. Glycerin 20g
4). 20g propylene glycol
5. Absolute ethanol 15g

精製水500gに対し主剤1、2を溶解させ、次いで4、5、6を入れて混合撹拌し、最後に3を入れて、更に混合撹拌して生体皮膜剤を得た。
1.塩化アルミニウム6水和物 40g
2.α−CD 10g
3.没食子水溶液(タンニン濃度10%) 100g
4.グリセリン 20g
5.プロピレングリコール 20g
6.無水エタノール 10g
●本実施例による<症例4>として、6歳男児、自宅で転倒し、左前額部を机の角にぶつけて左前額部骨膜を破り、前額部の骨膜を破り、骨皮質に僅かに傷が及ぶ深さの裂創を生じた。局所麻酔を行い電気メスで止血後、本皮膜剤を創内に散布し、縫合を行った後、再び、縫合部位の皮膚に塗布した。術後のケアとして、本皮膜剤を1日2回(朝・夜)継続塗布させた。術後経過は良好で、1週間後に全抜糸し、術後1ヵ月で瘢痕の赤みも少なく、従来の消毒と抗生物質軟膏塗布による治療や、術後のヘパリン類似物質による皮膚血流を促進する方法よりも、膠原線維の増生が少なく、硬さの少ないきれいな瘢痕を形成するに至っている。
The main ingredients 1 and 2 were dissolved in 500 g of purified water, and then 4, 5, and 6 were added and mixed and stirred. Finally, 3 was added and mixed and stirred to obtain a biofilm.
1. Aluminum chloride hexahydrate 40g
2. α-CD 10g
3. 100g of gallic aqueous solution (tannin concentration 10%)
4). Glycerin 20g
5. 20g propylene glycol
6). Absolute ethanol 10g
● As <Case 4> according to this example, a 6-year-old boy falls at home, hits the left forehead against the corner of the desk, breaks the left forehead periosteum, breaks the periosteum on the forehead, and slightly in the bone cortex A wound with a wound depth was created. After local anesthesia and hemostasis with an electric scalpel, the film agent was sprayed into the wound, sutured, and then applied again to the skin at the sutured site. As a post-operative care, this film agent was continuously applied twice a day (morning and evening). The postoperative course is good, the whole thread is removed one week later, scarring is scarce one month after surgery, treatment with conventional disinfection and antibiotic ointment, and postoperative heparin-like substance promotes skin blood flow It leads to the formation of clean scars with less collagen stiffness and less stiffness than the method.

精製水500gに対し主剤1、2を溶解させ、次いで4、5、6を入れて混合撹拌し、最後に3を入れて、更に混合撹拌して生体皮膜剤を得た。
1.塩化アルミニウム6水和物 40g
2.γ−CD 5g
3.柿渋濃縮タンニン(タンニン濃度15%) 100g
4.グリセリン 20g
5.プロピレングリコール 20g
6.無水エタノール 10g
●本実施例による<症例5>として、66歳男性。右第3趾背側面に生じたガングリオンの一例。局所麻酔下でガングリオンを摘出後、電気メスで止血後、本皮膜剤を創内及び、開いた遠位指節間関節の関節腔内に散布した。開いた遠位指節間関節部位は、周囲の関節滑膜が痛んでおり、閉鎖が困難な為、摘出したガングリオン上の皮膚を切離し、表皮を削除し、同関節上に真皮移植を行い、再び移植真皮上に散布し、皮膚縫合閉鎖した。皮膚縫合部位にも更に、本皮膜剤を塗り、手術を終了した。術後疼痛が極めて少なく、術後経過は良好で、抜糸までのケアとしては、縫合している為、本皮膜剤を1日2回(朝・夜)塗布、ガーゼとテーピングを行ない、術後2週間で順調に全抜糸。抜糸後のケアとして、1日2回(朝・夜)塗布、術後1ヵ月後の現在、ガングリオンの再発無く、ランニングや長時間のウォーキングを日課とする方であり、時に瘢痕部位が靴下や靴で擦れて出血する場面はあっても、瘢痕は赤みも硬さもなく、目立たない状態を保持している。
The main ingredients 1 and 2 were dissolved in 500 g of purified water, and then 4, 5, and 6 were added and mixed and stirred. Finally, 3 was added and mixed and stirred to obtain a biofilm.
1. Aluminum chloride hexahydrate 40g
2. γ-CD 5g
3. Strawberry concentrated tannin (tannin concentration 15%) 100g
4). Glycerin 20g
5. 20g propylene glycol
6). Absolute ethanol 10g
● A 66-year-old male as <Case 5> according to this example. An example of a ganglion produced on the right third dorsum. The ganglion was removed under local anesthesia, and after hemostasis with an electric scalpel, the film agent was sprayed in the wound and into the joint space of the open distal interphalangeal joint. Since the joint region of the distal interphalangeal joint is painful in the surrounding synovial membrane and difficult to close, the skin on the removed ganglion is removed, the epidermis is removed, and a dermal transplant is performed on the joint. It was again sprayed onto the transplanted dermis and the skin suture was closed. This skin agent was further applied to the skin suture site, and the operation was completed. Postoperative pain is very low, the postoperative course is good, and care is taken until the thread is removed. This film is applied twice a day (morning and evening), gauze and taping are performed. All yarns are steadily removed in 2 weeks. As a care after removal of the thread, it is applied twice a day (morning / night), 1 month after the operation, and the person who regularly runs and walks for a long time without recurrence of ganglion, sometimes the scar site is socks or Although there are occasions where the shoe rubs and bleeds, the scar is neither reddish nor stiff and remains inconspicuous.

精製水100mlに対し主剤1、2を溶解させ、24時間放置後に不溶

Figure 0005948687
させて、沈殿物を除いた溶液に戻し、次いで4、5を加えて撹拌して生体皮膜剤を得た。
1.塩化アルミニウム6水和物 10g
2.α−CD 5g
3.柿渋(タンニン濃度5%) 100g
4.グリセリン 20g
5.プロピレングリコール 20g
6.無水エタノール 5gDissolve main ingredients 1 and 2 in 100 ml of purified water and leave insoluble for 24 hours
Figure 0005948687
Then, the solution was returned to the solution from which the precipitate was removed, then 4, 5 was added and stirred to obtain a biofilm.
1. Aluminum chloride hexahydrate 10g
2. α-CD 5g
3. Strawberry shibu (tannin concentration 5%) 100g
4). Glycerin 20g
5. 20g propylene glycol
6). Absolute ethanol 5g

粉末ベース助剤100gに対して、主剤となる、塩化アルミニウム・6水和物 10g、β−CD 10g、柿渋タンニンのスプレードライ微粉末10gを陶製ボールミルに導入し、30分程、混合粉砕する。塩化アルミニウムの吸湿ブロック粉末を、粉末ベース助剤と混合粉砕することで、100メッシュパスの粉末状の生体皮膜剤が得られた。粉末ベース助剤は、亜鉛華40g、タルク40g、コーンスターチ澱粉20g、無水珪酸5gを配合して製造した。10 g of aluminum chloride hexahydrate, 10 g of β-CD, and 10 g of spray dried fine powder of persimmon tannin are introduced into a ceramic ball mill and mixed and ground for about 30 minutes with respect to 100 g of the powder base auxiliary agent. The powdered biological film agent of 100 mesh pass was obtained by mixing and pulverizing the moisture-absorbing block powder of aluminum chloride with the powder base auxiliary agent. The powder base auxiliary was produced by blending 40 g of zinc white, 40 g of talc, 20 g of corn starch starch, and 5 g of anhydrous silicic acid.

粉末ベース助剤100gと、主剤となる塩化アルミニウム・6水和物15g、γ−CD 8gを陶製ボールミルに導入して 25分程 粉砕することで、48メッシュパスの粉砕混合物として粉末状の生体皮膜剤が得られた。粉末ベース助剤は、活性亜鉛40g、タルク40g、コーンスターチ澱粉20g、無水珪酸微粉末5gを配合して製造した。Powder base auxiliary agent 100g, main ingredient aluminum chloride hexahydrate 15g, γ-CD 8g are introduced into a porcelain ball mill and pulverized for about 25 minutes. An agent was obtained. The powder base auxiliary was produced by blending 40 g of active zinc, 40 g of talc, 20 g of corn starch starch, and 5 g of anhydrous silicic acid fine powder.

発明の効果Effect of the invention

皮膚の擦過創、皮膚・皮下組織・筋膜・筋肉・軟骨・骨膜・骨に及ぶ、挫創、切創、裂創の創傷管理、痂皮形成、表皮化を早め、外傷及び術創の治癒期間を早め、皮膚の外傷性色素沈着や瘢痕を早く目立たなくする。Abrasion of skin, cutaneous wounds, cuts, wound management of wounds, scab formation, epidermis, covering the skin, subcutaneous tissue, fascia, muscle, cartilage, periosteum, and bone. Early, causing traumatic pigmentation and scarring of the skin to become less noticeable early.

開放性骨折時の際の急性炎症反応(腫脹・浮腫・疼痛)の低減、持続性炎症反応を抑制し、筋肉、骨組織の壊死や、二次感染による腐骨化を防止し、下肢切断という最終手段を回避する働きがある。Reduction of acute inflammatory reaction (swelling, edema, pain) at the time of open fracture, suppression of persistent inflammatory reaction, prevention of necrosis of muscle and bone tissue and ossification due to secondary infection, called lower limb amputation It works to avoid the last resort.

重症熱傷の際には、疼痛の管理を行った状態、静脈麻酔が施行できれば、その条件・状態で、全身皮膚にスプレー乃至は粉末散布器等で散布することにより、多量の浸出液を抑制又は吸着させることで、全身状態の悪化を抑制することができる。ポーラス状被膜構造は毛細血管の新生と膠原線維による肉芽組織の構築を妨げないので移植皮膚の正着率を増加させ、さらに生着した移植皮膚や皮膚採皮創部のケロイドや肥厚性瘢痕の形成を阻止するので、綺麗で伸縮性のある皮膚を形成することが可能となる。In the case of severe burns, if the pain is managed or if intravenous anesthesia can be performed, spray or powder sprayer etc. on the whole body skin under the conditions and conditions to suppress or adsorb a large amount of exudate By doing so, deterioration of the general condition can be suppressed. The porous capsule structure does not interfere with the formation of capillaries and the formation of granulation tissue with collagen fibers, thus increasing the rate of transplantation and the formation of keloids and hypertrophic scars in the transplanted skin and skin skin wound. Therefore, it is possible to form beautiful and stretchable skin.

手指や足趾の屈側及び、下顎頸部の熱傷において、本願複合皮膜が、ダメージ細胞の3次元的にコーチングすることから炎症反応の回避抑制に作用し、線維芽細胞の活動を抑制し過剰なコラーゲン線維の増生を抑え、創傷面に継時的に形成される肉芽組織の隆起を、本願複合皮膜により早期に形成される板状の血痂が圧迫整形しつつ表皮化が完了する結果、最短、且つ適切な創傷治癒過程が導かれ瘢痕拘縮を防止し、皮膚移植等の処置において手術前後で安心して使用できる利点があり、消炎作用と被膜作用は、疼痛と二次感染から回避し、皮膚移植の不要な浅い熱傷範囲の表皮化を促進するとともに、移植皮膚の正着率を増加させ、生着した移植皮膚や皮膚採皮創部のケロイドや肥厚性瘢痕の形成を阻止し、綺麗で伸縮性のある皮膚形成が可能となる。In the burned side of the fingers and toes, and in the burnt of the lower jaw neck, the composite film of the present application acts to suppress the inflammatory reaction because of the three-dimensional coating of damaged cells, and suppresses fibroblast activity and is excessive. As a result of suppressing epithelial growth of collagen fibers and completing the epidermis while the plate-like clot formed earlier by the composite film compresses and shapes the granulation tissue bulge formed on the wound surface over time, The shortest and appropriate wound healing process can be guided to prevent scar contracture, and there is an advantage that it can be used safely before and after surgery in procedures such as skin transplantation, and anti-inflammatory and capsule effects are avoided from pain and secondary infection. Promotes epidermalization of shallow burn areas that do not require skin transplantation, increases the rate of transplanted skin, and prevents the formation of keloids and hypertrophic scars on the transplanted skin and skin skin wounds. With elastic skin formation The ability.

手指や足趾の屈側及び、下顎頸部の熱傷において、ダメージ細胞の3次元的コーチングによる炎症反応の回避抑制により、線維芽細胞の活動を抑制し、過剰なコラーゲン線維の増生を抑え、最短で適正な創傷治癒過程に導くことにより、瘢痕拘縮を防止し、屈曲拘縮や伸展制限等の機能障害、行為障害を回避し、また皮膚の醜形を回避する。Suppresses fibroblast activity and suppresses excessive collagen fiber growth by suppressing the avoidance of inflammatory response by three-dimensional coaching of damaged cells in the burned side of fingers and toes, and mandibular neck By leading to an appropriate wound healing process, scar contracture is prevented, dysfunctions such as flexure contracture and extension restriction, and behavioral disorders are avoided, and skin wrinkles are avoided.

消化管、肝胆道系、呼吸器系、婦人科系の各手術における縫合不全を防止する。術後の炎症性浮腫の出現期間を短縮し、入院期間を短縮し、社会復帰を早める。しかし心臓循環器系への使用、血管吻合への使用においてはタンニン(タンニン酸)濃度、適用条件によっては血栓形成の可能性が考えられるので細心の注意が必要となる。Prevent suture failure in digestive tract, hepatobiliary system, respiratory system, gynecological surgery. Shorten the period of appearance of inflammatory edema after surgery, shorten hospital stays, and speed up rehabilitation. However, in the use for the cardiovascular system and the use for vascular anastomosis, the tannin (tannic acid) concentration and the application conditions may be considered to cause thrombus formation.

癌の局所療法として、制癌剤(抗がん剤)を混合し、癌の主病巣や転移癌の部位に塗布乃至は散布することで、癌の病巣を被覆し、播種性転移を防ぐとともに、癌の縮小効果を得る治療が可能となる。癌細胞をはじめ生体内の諸臓器組織においても簡便に使用でき、遺残しても何らの弊害を伴うこともないので、現状のがん治療に有効、且つ安価に施行し得る代替手段となる。As a local treatment for cancer, anticancer drugs (anticancer drugs) are mixed and applied to or spread on the main lesions or sites of metastatic cancer to cover the cancer lesions and prevent disseminated metastasis, as well as cancer. It is possible to achieve a reduction effect. Since it can be used easily in various organ tissues in the body including cancer cells, and it does not cause any adverse effects even if left behind, it is an alternative means that is effective for current cancer treatment and can be implemented at low cost.

Claims (5)

主剤が塩化アルミニウムとシクロデキストリンとタンニン(タンニン酸)と水とを含む、皮膚及び皮下組織の創傷面及び諸臓器、諸臓器障害部位、並びに骨膜、骨皮質に達する創傷面での被覆及び庇護を目的とし、障害細胞を被覆する生体皮膜剤。Covers and protects the wound surface and organs of the skin and subcutaneous tissues, the site of organ damage, and the wound surface reaching the periosteum and bone cortex, the main ingredients include aluminum chloride, cyclodextrin, tannin (tannic acid) and water A biofilm agent that is intended to coat damaged cells. 塩化アルミニウムの濃度が、水100部に対して、0.01〜25.0重量%である請求項1に記載の生体皮膜剤。The biofilm agent according to claim 1, wherein the concentration of aluminum chloride is 0.01 to 25.0 wt% with respect to 100 parts of water. シクロデキストリン濃度が、水100部に対して、0.1〜45重量%の範囲である、請求項1に記載の生体皮膜剤The biofilm agent according to claim 1, wherein the cyclodextrin concentration is in the range of 0.1 to 45% by weight with respect to 100 parts of water. タンニン(タンニン酸)の濃度が、水100部に対して、0.01〜50.0重量%である、請求項1に記載の生体皮膜剤The biofilm agent according to claim 1, wherein the concentration of tannin (tannic acid) is 0.01 to 50.0 wt% with respect to 100 parts of water. 主剤となる水が、体液中の水分(汗汁、鼻汁、涙液、唾液、気管及び気管支分泌液、血液、炎症性浸出液、胃粘液及び胃液、小腸粘液、胸水、覆水、後腹膜腔諸臓器表面を潤す水、縦隔の心、大血管を潤す水、子宮頸管粘液、膣分泌液、肛門腺分泌液等の生体水分)である、粉末状の請求項1に記載の生体皮膜剤The main ingredient is water in body fluids (sweat, nasal discharge, tears, saliva, trachea and bronchial secretions, blood, inflammatory exudate, gastric mucus and gastric juice, small intestinal mucus, pleural effusion, lining fluid, retroperitoneal organs 2. Powdered biological coating agent according to claim 1, which is water that moisturizes the surface, water of the mediastinum, water that moisturizes the large blood vessels, cervical mucus, vaginal secretion, anal gland secretion, etc.
JP2015169762A 2015-08-12 2015-08-12 A biofilm for the purpose of promoting wound healing and covering (coaching) and protecting living organs. Active JP5948687B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2015169762A JP5948687B1 (en) 2015-08-12 2015-08-12 A biofilm for the purpose of promoting wound healing and covering (coaching) and protecting living organs.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015169762A JP5948687B1 (en) 2015-08-12 2015-08-12 A biofilm for the purpose of promoting wound healing and covering (coaching) and protecting living organs.

Publications (2)

Publication Number Publication Date
JP5948687B1 true JP5948687B1 (en) 2016-07-06
JP2017035425A JP2017035425A (en) 2017-02-16

Family

ID=56329559

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015169762A Active JP5948687B1 (en) 2015-08-12 2015-08-12 A biofilm for the purpose of promoting wound healing and covering (coaching) and protecting living organs.

Country Status (1)

Country Link
JP (1) JP5948687B1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002060320A (en) * 2000-07-12 2002-02-26 Beiersdorf Ag Cosmetic and dermatologic composition to eliminate sebum
WO2004091640A1 (en) * 2003-04-11 2004-10-28 Hououdou Co.,Ltd. Skin protecting compositions
WO2012063947A1 (en) * 2010-11-12 2012-05-18 日産化学工業株式会社 Gel sheet comprising lipidic peptide type gelling agent and polymeric compound
WO2015099083A1 (en) * 2013-12-25 2015-07-02 日産化学工業株式会社 Aqueous dispersion for solidifying serum and blood
JP5796728B1 (en) * 2014-11-17 2015-10-21 株式会社ライラック研究所 A biofilm for the purpose of promoting wound healing and covering (coaching) and protecting living organs.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002060320A (en) * 2000-07-12 2002-02-26 Beiersdorf Ag Cosmetic and dermatologic composition to eliminate sebum
WO2004091640A1 (en) * 2003-04-11 2004-10-28 Hououdou Co.,Ltd. Skin protecting compositions
WO2012063947A1 (en) * 2010-11-12 2012-05-18 日産化学工業株式会社 Gel sheet comprising lipidic peptide type gelling agent and polymeric compound
WO2015099083A1 (en) * 2013-12-25 2015-07-02 日産化学工業株式会社 Aqueous dispersion for solidifying serum and blood
JP5796728B1 (en) * 2014-11-17 2015-10-21 株式会社ライラック研究所 A biofilm for the purpose of promoting wound healing and covering (coaching) and protecting living organs.

Also Published As

Publication number Publication date
JP2017035425A (en) 2017-02-16

Similar Documents

Publication Publication Date Title
JP6778219B2 (en) Igai adhesive protein products that suppress skin inflammation and their applications
EP3308793B1 (en) Therapeutic agent for skin wound or rough skin
US20130252921A1 (en) Adhesion barrier containing hyaluronic acids and l-arginine
US8426384B2 (en) Wound-healing pharmaceutical compositions in the form of a sterile powder based on amino acids and sodium hyaluronate
CA2966724C (en) Biological film-forming agent for facilitation of wound healing and coating and protection of biological organs
RU2009107068A (en) APPLICATION OF PROPYLENE GLYCOL IN THE TREATMENT OF INFLAMMATORY LOCAL DISORDERS OR DISEASES ASSOCIATED WITH INFLAMMATION
JP5948687B1 (en) A biofilm for the purpose of promoting wound healing and covering (coaching) and protecting living organs.
CA2404210C (en) Pharmaceutical gel composition
US11260111B2 (en) Mussel adhesive protein product and applications thereof in suppression of skin inflammations
WO2006094064A2 (en) Method of reducing scars with vitamin d
AU2001242100B2 (en) Pharmaceutical gel composition
WO2019178658A3 (en) Healing, moisturizing, humectant and emolient composition for topical administration in intertrigo skin lesions, skin lesions due to urinary and faecal incontinence and other related injuries.
Namviriyachote et al. Sulfadiazine Cream Treatment of Chemical Burn with Topical Silver Zinc Sericin Sulfadiazine Cream
AU2001242100A1 (en) Pharmaceutical gel composition

Legal Events

Date Code Title Description
A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20160413

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160517

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160519

R150 Certificate of patent or registration of utility model

Ref document number: 5948687

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250